Pfizer’s (NYSE:PFE) Rheumatoid Arthritis drug ~ Xeljanz ~ is a comparatively small drug with gros
Pfizer’s (NYSE:PFE) Rheumatoid Arthritis drug ~ Xeljanz ~ is a comparatively small drug with gross sales of round $2 billion, and it accounts for round 4% of the entire rheumatoid arthritis medication market. AbbVie’s Humira is the chief primarily based on drug’s whole gross sales. Nevertheless, Humira is used for different indications as effectively, comparable to Crohn’s Illness and Ulcerative colitis amongst others. Rheumatoid arthritis refers to a long run autoimmune dysfunction associated to joints. Pfizer’s Xeljanz is protected against any biosimilar competitors until 2025, and it might see gross sales progress within the close to time period. The drug has demonstrated to be non-inferior to Humira for sufferers with average to extreme rheumatoid arthritis. Nevertheless, gross sales progress will doubtless be slower going ahead, amid robust competitors from different pharmaceutical firms within the crowded rheumatoid arthritis medication market.
The market (ten medication listed within the dashboard) is anticipated to see a decline in gross sales going ahead, as J&J’s Remicade is going through biosimilar competitors after its patent loss in 2016, and it already misplaced $1.6 billion in gross sales between 2016-2018. It’ll doubtless lose one other $2.6 billion by 2021, in our view, thus offsetting the expansion from different…